Skip to main content

Table 4 The detail of side effect between RGC patients with SMIHigh and those with SMILow

From: Impact of skeletal muscle mass in patients with recurrent gastric cancer

 

SMIHigh (n = 34)

SMILow (n = 33)

p value

All side effect of grade 3 or 4

  

0.010

 Positive

11 (32.4)

21 (63.6)

 

 Negative

23 (67.6)

12 (36.4)

 

Neutropenia of grade 3 or 4

  

0.267

 Positive

10 (29.4)

14 (42.4)

 

 Negative

24 (70.6)

19 (57.6)

 

Anaemia of grade 3 or 4

  

0.975

 Positive

2 (5.9)

2 (6.1)

 

 Negative

32 (94.1)

31 (93.9)

 

Thrombocytopenia of grade 3 or 4

  

0.968

 Positive

1 (2.9)

2 (6.1)

 

 Negative

33 (97.1)

31 (93.9)

 

Gastrointestinal toxicity

  

0.018

 Positive

2 (5.9)

9 (27.3)

 

 Negative

32 (94.1)

24 (72.7)

 

FN

  

0.215

 Positive

2 (5.9)

5 (15.2)

 

 Negative

32 (94.1)

28 (84.8)

 
  1. Data are presented as number (percentage) of patients
  2. RGC recurrent gastric cancer, SMI skeletal muscle mass, SMIHigh high skeletal muscle mass, SMILow low skeletal muscle mass